IMPACT Therapeutics Inc. (Ticker: 7630 HK) is a Chinese commercial-stage biotechnology company focused on synthetic lethality-based precision anti-cancer therapies. Founded in 2009, the company’s core product is senaparib, commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer, with additional oncology indications under clinical evaluation. Its pipeline also includes other clinical-stage and preclinical drug candidates, including ADC and degrader candidates.

IMPACT Therapeutics plans to list on the Hong Kong Stock Exchange Main Board on May 13, 2026. According to published terms, the company is offering 41.98 million H shares at an expected price range of HKD 19.75-21.75 per share, raising approximately HKD 913 million, or about $116 million. The implied market capitalization is approximately $696-767 million. The offering consists entirely of primary shares, with a 15% greenshoe option.

According to the prospectus, proceeds will be used for R&D and product capacity, brand promotion and business development, working capital, and strategic acquisitions. The IPO sponsors are CICC Hong Kong Securities and Goldman Sachs (Asia).